Tezepelumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TSLP |
Clinical data | |
Synonyms | MEDI9929, AMG 157 |
Routes of administration | Subcutaneous injection |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6400H9844N1732O1992S52 |
Molar mass | 144.6 kDa |
Tezepelumab (INN) (MEDI9929, AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis.[1][2] It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[3]
This drug is being developed in collaboration by MedImmune, LLC and Amgen.
It is in Phase III trials as of October 2018.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab, American Medical Association.
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ↑ Tezepelumab granted Breakthrough Therapy Designation by US FDA - AstraZeneca Press Release
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.